UK HEALTH TECHNOLOGY ASSESSMENT OF ORPHAN DRUGS FOR RARE ONCOLOGY VERSUS RARE DISEASE: DOES ORPHAN DESIGNATION MAKE ANY DIFFERENCE IN HTA PROCESS?

被引：0
|
作者：
Kelly, S. [1 ]
机构：
[1] Charles River Associates Inc, London, England
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2754
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY180
引用
收藏
页码：S467 / S467
页数：1
相关论文
共 15 条
  • [1] Health technology assessment: oncology drugs with orphan designation as an example
    Claudia Wild
    [J]. Orphanet Journal of Rare Diseases, 5 (Suppl 1)
  • [2] Analysis of Health Technology Assessment (HTA) Procedures and Outcomes for Orphan Drugs
    Warttig, S.
    D'Souza, V
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S334 - S335
  • [3] PROVISIONS AND SPECIAL CONSIDERATIONS FOR RARE DISEASES / ORPHAN DRUGS BY HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES: SYSTEMATIC EVALUATION IN 25 COUNTRIES
    Mwamburi, M.
    Nanavaty, M.
    Gala, S.
    Nyandege, A.
    Ramesh, V
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A602 - A602
  • [4] Orphan Drugs for Rare Diseases: Debating the Challenges of Health Commissioning in the UK
    Ticehurst, Flo
    [J]. JOURNAL OF MEDICAL GENETICS, 2008, 45 : S103 - S103
  • [5] THE QUANTITY AND QUALITY OF EVIDENCE SUPPORTING EUROPEAN MARKETING AUTHORISATION OF ORPHAN DRUGS: COMPARISON OF RARE ONCOLOGY VERSUS RARE DISEASE
    Kelly, S.
    [J]. VALUE IN HEALTH, 2018, 21 : S468 - S468
  • [6] Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
    Malinowski, Krzysztof Piotr
    Kawalec, Pawel
    Trabka, Wojciech
    Sowada, Christoph
    Petrova, Guenka
    Manova, Manoela
    Savova, Alexandra
    Draganic, Pero
    Slaby, Juraj
    Mannik, Agnes
    Marky, Kristof
    Rugaja, Zinta
    Gulbinovic, Jolanta
    Tesar, Tomas
    Paveliu, Marian Sorin
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2020, 15 (01)
  • [7] Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
    Krzysztof Piotr Malinowski
    Paweł Kawalec
    Wojciech Trąbka
    Christoph Sowada
    Guenka Petrova
    Manoela Manova
    Alexandra Savova
    Pero Draganić
    Juraj Slabý
    Agnes Männik
    Kristóf Márky
    Zinta Rugaja
    Jolanta Gulbinovic
    Tomas Tesar
    Marian Sorin Paveliu
    [J]. Orphanet Journal of Rare Diseases, 15
  • [8] HEALTH TECHNOLOGY ASSESSMENT (HTA) FOR ORPHAN DRUGS IN COST-EFFECTIVENESS (CE) MARKETS: CURRENT DEVELOPMENT AND FUTURE TRENDS
    Zhang, A.
    Weisse, S.
    Chen, X.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A601 - A601
  • [9] HOW DO RARE DISEASE PATIENT NUMBERS IN GERMANY AFFECT THE PRICE OF NON-ONCOLOGY ORPHAN DRUGS?
    Patel, B.
    Matthews, C.
    Male, O.
    [J]. VALUE IN HEALTH, 2020, 23 : S704 - S704
  • [10] Societal Preferences in Health Technology Assessments for Rare Diseases and Orphan Drugs: A Systematic Literature Review of New Analytic Approaches
    Vasquez, Paola
    Hall, Lisa
    Merlo, Gregory
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2024, 44
12